What is HC Wainwright’s Forecast for ETON FY2027 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research report issued on Monday, January 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $1.27 per share for the year, up from their previous forecast of $1.25. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Trading Up 0.2 %

NASDAQ ETON opened at $12.01 on Wednesday. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $15.00. The company has a market cap of $312.87 million, a PE ratio of -54.59 and a beta of 1.38. The stock’s 50-day moving average price is $11.57 and its two-hundred day moving average price is $7.32.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the third quarter worth approximately $54,000. Jane Street Group LLC purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC boosted its stake in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.